The short answer
Semaglutide sodium and semaglutide base are not interchangeable names. FDA says the sodium and acetate salts are different active ingredients from the base used in approved semaglutide drugs. The agency does not know whether those salts have the same chemical and pharmacologic properties. It also says it is unaware of a lawful basis for their use in compounding under the applicable federal conditions. [1]
For background, see why vitamin B12 is added to semaglutide before applying a general claim to a particular product.
That distinction concerns the ingredient itself. It is separate from whether a pharmacy is licensed, whether a prescriber issued an order, or whether a laboratory reported high purity. Those questions still matter, but a satisfactory answer to one does not settle the others. A prescription does not turn a different substance into the ingredient in an approved medicine.
What “base” does and does not tell you
A pharmacy identifying the base form answers an important identity question. It does not establish that its finished vial is FDA-approved, equivalent to a branded pen, or supported by the branded product’s trials. Compounding can change concentration, added ingredients, packaging and instructions. FDA does not review a compounded product for safety, effectiveness and quality before marketing. [2]
Think of identity as the first field on a label rather than the entire quality assessment. You still need to know who prepared the product, its exact concentration, its storage requirements and its discard date. A correct ingredient name cannot replace those details. Equally, a missing suffix on a marketing page is not proof of which form the pharmacy actually used.
Why a certificate of analysis is not the whole answer
A certificate can identify a tested sample and report the tests performed on that material. It cannot, by itself, connect an anonymous online powder to a patient’s finished prescription. Ask whether the report concerns the raw ingredient or the dispensed preparation, and whether its lot identifier matches the relevant records. Avoid treating a purity percentage as a clinical outcome.
There are two different claims to examine: that the supplier provided the stated material, and that the finished formulation is appropriate for a particular patient. A laboratory result addresses only its stated test and sample. The prescribing decision and the pharmacy’s quality controls remain separate. FDA’s compounding guidance explains why compounded products and approved generics are different categories. [3]
Questions worth sending to the pharmacy
Ask for the exact active ingredient name, including whether it is semaglutide base, sodium or acetate. Ask the dispensing pharmacy to answer in writing. A platform’s general statement that it uses the same ingredient as a brand does not identify your specific preparation. Provide the prescription number and lot number privately so the pharmacist can trace the actual vial.
Also ask whether other active ingredients have been added. FDA says the safety and effectiveness of combining semaglutide with ingredients such as vitamin B12 have not been established. [2] That does not prove every combination causes harm. It means evidence from an approved semaglutide product cannot be silently extended to the entire mixture.
If the package does not match the advertisement
Keep photographs of the label and packaging. Contact the pharmacy and prescriber before using a product with an unexplained ingredient name or inconsistent instructions. Do not remove a label, rewrite it yourself, or substitute a dose calculation from another vial. The concentration and identity should be resolved together by the professionals responsible for the prescription.
FDA recommends obtaining prescription GLP-1 medicines through a state-licensed pharmacy. Its current warning also highlights misleading equivalence claims, broken packaging, missing instructions and incorrect pharmacy addresses. [1] An attractive website or a low advertised monthly price cannot answer these identity questions. A pharmacy that can explain the exact product gives you information you can assess.
What this means for a buying decision
Start with the exact finished product being offered. If an approved medication can meet your medical needs, discuss that route with the prescriber. FDA says compounded medicines should be used only when a patient’s medical needs cannot be met by an approved drug. [1] Affordability matters, but price does not establish ingredient identity, approval or therapeutic equivalence.
An unresolved salt-form question is a reason to pause the purchase and get a documented answer. It is not a reason to search for a home conversion or a different research chemical. The useful comparison is between legitimate care options with clear ingredients, accountable dispensing and understandable instructions. That gives the prescriber a concrete product to evaluate.
Read the evidence in context
See why vitamin B12 is added to semaglutide for the related details and source material.
See reading a peptide certificate of analysis for the related details and source material.
See peptide legality and compounding for the related details and source material.